Abstract:Imatinib mesylate (Gleevec or STI-571), a tyrosine kinase inhibitor, can potently block both platelet-derived growth factor (PDGF) receptor-α and β by inhibiting the receptor tyrosine kinase activity. Imatinib mesylate has been successfully used to treat patients with chronic myeloid leukemia (CML) and Ph positive acute lymphoid leukemia (ALL). However, a significant number of patients with imatinib mesylate treatment have developed neutropenia, thrombocytopenia and anemia (van Deventer, Hall et al. 2002). Our previous studies have demonstrated that PDGF/PDGFR plays an important role on thrombopoiesis, and blockage of PDGFR by imatinib inhibited the downstream signal pathway, which led to reduce of megakaryocyte production (Ye, et al. Haematologica, 2010). This may partially explain the imatinib-related thrombocytopenia. However, the role of imatinib on normal hematopoiesis remains to be investigated. In the present study, we identified the expression of PDGFR-β on the human megakaryoblastic cells: Meg-01, CHRF-288-11, Dami and M-07e, human erythromyeloblastoid leukemia cells: K-562 and human myeloblastic cells: HL-60 by RT-PCR, western blot and flow cytometry. We then demonstrated the effect of imatinib on normal hematopoiesis in the 8 wk old C57BL/6 mice model. Gleevec (25 mg/kg/day) dissolved in distilled water or water only were given orally for up to 2 wks. 15ul whole blood was taken from postorbital weekly to perform blood cell counts. The Gleevec -treated group showed a reduction of platelet count as compared to the control at day 14 (543.3±71.95×109/L vs. 330.0±62.23×109/L, n=5, P<0.05). Similarly, Gleevec caused a significant decrease in the number of white blood cells on day 14 (9.667×±0.8511×109/L vs. 6.080±0.8015×109/L, n=5, P<0.05). While no significant differences were found on red blood cell count between Gleevec and control groups. The mice bone marrow was harvested from each group to perform CFU assays. Gleevec significantly inhibited the formation of bone marrow CFU-MK (15.33±1.764 vs 3.333±0.6667, n=3), and CFU-GM(13.50±2.784 vs 6.333±0.7265, n=3) compared with the control. There were no significant differences found in CFU-GEMM and CFU/BFU-E formation between the Gleevec and control treatment. Our studies suggested that PDGFR were expressed on hematopoietic cells. Imatinib mesylate, an inhibitor of PDGFR, not only played an important role in malignant hematopoiesis, but also in normal hematopoiesis. Administration of Gleevec reduced white blood cells and megakaryocytes/platelets production, which implied its potential therapeutic role in treating myeloproliferative diseases, such as Essential Thrombocytosis.

[Molecular Mechanism of Imatinib-Induced Thrombocytopenia in Treatment of Patients with CML].

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Resistance Mechanism of Imatinib Therapy in Gastrointestinal Stromal Tumors

Imatinib Mesylate Has an Inhibitory Effect on Hematopoiesis in A Mice Model

Efficacy analysis of imatinib in treatment of patients with chronic myeloid leukemia

Therapeutic Effects of Imatinib on Chronic Myeloid Leukemia in Different Phases and the Factors Affecting the Effects

Progress of the BCR-ABL and Src family kinases interactions leading CML to imatinib-resistance

Imatinib and Bortezomib Induce the Expression and Distribution of Anaphase-Promoting Complex Adaptor Protein Cdh1 in Blast Crisis of Chronic Myeloid Leukemia.

[Analysis of Efficacy and Related Factors in 85 Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate].

Platelet-derived Growth Factor Enhances Platelet Recovery in a Murine Model of Radiation-Induced Thrombocytopenia and Reduces Apoptosis in Megakaryocytes Via Its Receptors and the PI3-k/Akt Pathway

The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia

Detection of Imatinib in the Plasma and Its Effect in the Patient with Chronic Myeloid Leukemia

Inhibitory Effects of Imatinib Mesylate on Human Epidermal Melanocytes.

[The Efficacy of Imatinib Mesylate for 124 Patients with Chronic Myeloid Leukemia in Accelerated and Blastic Phase].

[Efficacy of Imatinib Mesylate, a Specific Inhibitor of BCR/ABL Tyrosine Kinase, on Chronic Myeloid Leukemia in Blast Phase].

Effect of imatinib mesylate on expression of vascular endothelial growth factor in bone marrow cells of chronic myeloid leukemia

Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review

The molecular mechanism of Gleevec in treating CML

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Mechanisms of Imatinib Mesylate Induced Apoptosis of Primary T Cells

Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia